Brokerage UBS prefers Solar Pharma and Cipla amongst Indian drugmakers and expects the shares to return 26% and 23%, respectively, over Friday’s closing.
“In India additionally, the expansion of India pharma market has been slowing and up to date traits of sharp enhance in unbranded generics is a priority,” stated UBS analysts in a consumer be aware. “These two markets account for 70-80% of sector earnings and would indicate decrease development.”
Businesses
